Healio Rheumatology HealioRheum
2 years 3 months ago
🏆Dr. Georg Schett's pioneering work in CAR-T for #autoimmune disease has landed him among the TIME100 Most Influential People in Health
“Not only are the patients in drug-free remission, but I believe many are cured of their autoimmune disease," he said
https://t.co/Rj7FpkluNg
Dr. John Cush RheumNow
2 years 3 months ago
Full read review of IL-18 binding protein, natural antagonist of IL-18 . https://t.co/cGVQeyrXd9 https://t.co/XRhk9Ut0TN
Dr. John Cush RheumNow
2 years 3 months ago
Biology and Rx of Lupus Flares
https://t.co/VlaI1PK8X8 https://t.co/oFXqGUvL4b
Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.
Peter Nash drpnash
2 years 3 months ago
CAR T-Cell Therapy in Autoimmune Disease | New England Journal of Medicine https://t.co/VKlNGVDfyw. - persistence of CAR-T cells needs exploration
Dr. John Cush RheumNow
2 years 3 months ago
Biomarker Predictors of Osteoarthritis
Science Advances has reported that Duke University researchers have validated a biomarkers of osteoarthritis that may be identified 2 years before the appearance of radiographic OA. S
https://t.co/T9XQ3x9yc2 https://t.co/HdwbXR1nDX
Dr. John Cush RheumNow
2 years 3 months ago
ARCTIC Rewind: Can You Taper DMARDs with Remission?
https://t.co/5Mkdyt4DIK https://t.co/0Z2gVpjIgX
The Rotterdam study shows that weight-bearing recreational physical activity caused more incident knee osteoarthritis (KOA), but mainly when there was low muscle mass. KOA risk is traditionally linked to either obesity or injury. This study assesses whether muscle mass may influence osteoarthritis risk.
Dr. John Cush RheumNow
2 years 3 months ago
Very late onset Lupus (>60) is less female, less arthritis/dz activity, lower dsDNA, C3, SSA, SSB and ANA but more Sjogrens & RA? Single clinic study of 845 SLE - jSLE (<18), aSLE (18-49), lSLE (50-60), and vlSLE (>60). vlSLE had lowest survival (20yrs) https://t.co/i3nQPVGYeP https://t.co/fiJe1g3AI3
Dr. John Cush RheumNow
2 years 3 months ago
TLR Antagonist in Lupus
An investigational TLR ) antagonist was effective in reducing biomarkers and clinical symptoms of SLE in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.
https://t.co/QSX3fRXRLs https://t.co/jt5nVer2ZQ
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: What are the Early Stages of Lupus?
https://t.co/2ACuh2WirF
A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).ILD affects ~23% of DM patients and the oft used MTX is has a low risk of pneumonitis and pulmonary fibrosis in 0.3% to 11.6% (in RA), respectively. Such risks have caused concern regarding the potential benefits vs. risk of using MTX in ILD.
Dr. John Cush RheumNow
2 years 3 months ago
Mexican study 202 #SLE pts shows 89 (45.1%) were hospitalized; their profile was they were younger, shorter Dz duration, higher disease activity scores (SLEDAI), and more damage. Hosp were for Dz activity (61%), Renal Dz, infection, drug toxicity (5.6%)https://t.co/3TKb1ck18V https://t.co/om2R3kfpFY
Dr. John Cush RheumNow
2 years 3 months ago
Study of f 234 AAV pts. 85 (36%) developed diffuse alveolar haemorrhage. Independent predictors of DAH: 1) Age [OR=1.037); 2) PLT # [OR=0.996]; 3) ESR [OR=1.028]; 4) HgB [OR=0.978]; 5) hematuria [OR=3.77] https://t.co/eKOu5PHs4R https://t.co/mGwLAVJhAN
